Pacific Biosciences of California Inc. buy UBS Group AG
Start price
17.11.23
/
50%
€7.17
Target price
17.11.24
€9.20
Performance (%)
-77.02%
Price
10.05.24
€1.65
Summary
This prediction is currently active. Massive losses of -77.02% have been the result for the BUY prediction by UBS_Group_AG. This prediction currently runs until 17.11.24. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacific Biosciences of California Inc. | -2.808% | -2.808% |
iShares Core DAX® | 4.094% | 3.543% |
iShares Nasdaq 100 | 1.424% | 0.512% |
iShares Nikkei 225® | -1.572% | -4.633% |
iShares S&P 500 | 1.822% | 0.963% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€5.53
16.02.24
16.02.24
€11.13
16.02.25
16.02.25
-70.18%
10.05.24
10.05.24